Dawn Belt Davis, MD, PhD talks about hopeful T1D breakthroughs coming in 2018. She’s the associate professor in the division of endocrinology, diabetes and metabolism at the University of Wisconsin School of Medicine. Davis speaks about exciting research in islet transplantation, 670g artificial pancreas system, insulin pumps and more. Lets hope that 2018 brings major advances in the condition while bringing possible cures for type 1 diabetes.
I'm a type 1 diabetic with diabetes knowledge in t1d and t2d, as well as nutrition and low-carb keto diet information, fitness and exercise programs to help keep you in optimal diabetes health. Take advantage of our diabetic health tools for a healthier lifestyle!
Bionic Pancreas Critical Hurdle! Beta Bionics recently won $12 million in supplemental funding from the National Institutes of Health (NIH) to conduct a major multicenter, national clinical trials for the iLet™ (bionic pancreas). Developed by Edward Damiano (Beta Bionics) and Firas El-Khatib. They hope to have the device approved for market in about a year….
Scientists at SymbioCellTech (SCT) have developed a technology called Neo Islets for possible type 1 diabetes (T1D) cure. It combines Mesenchymal Stem Cells (MSCs) with culture-expanded pancreatic islet cells to form three-dimensional cellular clusters. The scientists performed the technique in mice. All treated mice demonstrated normal blood glucose control without the need for anti-rejection drugs or encapsulation devices….
DIABECELL is a cell therapy where insulin producing islet cells are taken from the pancreas of a pig. The islets are then encapsulated into an alginate material. The encapsulated porcine cells are then implanted into the abdomen of patient’s with type 1 diabetes. It’s done via an easy laparoscopic procedure. After the procedure, the self-regulating…
Previously Published on Diabetes Daily ViaCyte Interview By Christine Fallabel – I recently had the opportunity to sit down with Manasi Sinha Jaiman, M.D., M.P.H., Vice President of Clinical Development, and Mark Daniels, Senior Director of Clinical Development, of ViaCyte, “a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all…
Previously Published on Medscape.com – A US Food and Drug Administration (FDA) advisory panel has voted narrowly to recommend approval of the monoclonal antibody teplizumab (Tzield,Provention Bio) for the delay of type 1 diabetes in at-risk individuals. (FDA Endorses Teplizumab) The 10-7 vote of the FDA’s Endocrinologic and Metabolic Drugs advisory committee on May 27 reflected a…
Previously Published on Fiercebiotech.com – Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The all-cash deal announced Monday throws a net around ViaCyte’s stem cell-based treatment for type 1 diabetes, which has…